Screener
4D Molecular Therapeutics FDMT Contract Liabilities
Contract Liabilities at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Deferred revenue | 360 | 360 |
| Operating lease liabilities, current portion | 5,486 | 5,592 |
| Total current liabilities | 43,404 | 43,985 |
| Deferred revenue, net of current portion | 2,125 | 745 |
| Derivative liability | 370 | 358 |
| Operating lease liabilities, long-term portion | 15,049 | 15,821 |
| Other liabilities | 121 | 138 |
| Total liabilities | 61,069 | 61,047 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's contract liabilities?
- 4D Molecular Therapeutics (FDMT) reported contract liabilities of $2.13M in Q1 2026.
- How has 4D Molecular Therapeutics's contract liabilities changed year-over-year?
- 4D Molecular Therapeutics's contract liabilities increased by 389.6% year-over-year, from $434K to $2.13M.
- What is the long-term trend for 4D Molecular Therapeutics's contract liabilities?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's contract liabilities has grown at a -43.7% compound annual growth rate (CAGR), from $13.23M to $745K.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about 4D Molecular Therapeutics's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude